header_pipeline

Our Pipeline and Progress

Developing first-in-class Nck modulators for autoimmune disease

Our first-in-class, novel mechanism holds broad potential to treat T cell mediated autoimmune diseases such as psoriasis, atopic dermatitis, psoriatic arthritis, ankylosing spondylitis, and many others, while simultaneously allowing the body to fight foreign pathogens.

AX-158
Discovery
Preclinical
Phase 1
Phase 2
Next Milestone
Psoriasis
Phase 2
Data Q4 2024
Atopic dermatitis
Phase 2
Start Phase 2 in 2025
Autoimmune disease
Phase 1
AX-194
Discovery
Preclinical
Phase 1
Phase 2
Next Milestone
CAR-T, I/O
Preclinical
Start Phase 1 in 2026

Psoriasis

Psoriasis is an autoimmune disease affecting the skin. It causes a rash with itchy, scaly patches, most commonly on the knees, elbows, trunk, and scalp. Psoriasis is a long-term disease with no cure. It can be painful, interfere with sleep, and make it hard to concentrate. It is estimated that more than 7 million adults in the US have psoriasis today. AX-158 is an oral agent currently being tested in patients with mild to moderate psoriasis, with first results expected in Q4 2024.

Atopic dermatitis

Atopic dermatitis (atopic eczema) is a chronic, relapsing, and remitting inflammatory skin disease affecting one in 10 people in their lifetime. Repeated scratching triggers a self-perpetuating itch-scratch cycle, which can have a significant impact on the patient’s quality of life. We plan to initiate a Phase 2 clinical trial with AX-158 in patients with moderate to severe atopic dermatitis in 2025.

Autoimmune disease

We also plan to investigate the potential efficacy and safety of AX-158 in an additional autoimmune indication.

Additional programs

We are developing additional Nck modulator candidates. AX-194 is undergoing preclinical testing to enter Phase 1 clinical safety trials in healthy human volunteers in 2026.